SCITECH PHARMA
SciTech Pharma is an innovative drug design and drug discovery company.
Our professional team has been at the forefront of using Artificial Intelligence for the design and discovery of new drugs since 2003.
Using our proprietary Sigma HIT®program, we have successfully designed numerous new drug candidates that are in various stages of drug development.
RESEARCH & DEVELOPMENT
SciTech Pharma designs Class I Small Molecule Drugs that focus on the treatment of:
Oncology
Autoimmune Disease
Central Nervous System Disease
Through the rapid synthesis and optimization of desired small molecules, we achieve target validation, lead discover, lead optimization, preclinical studies and clinical evaluation to deliver the best-in-class drugs from conception to patients.
In the future, our SigmaHIT® Drug Design Program will extend to new areas of drug design and discovery, including, but not limited to, Large Molecule Drugs.
MEDIA CENTER
-
2024-04-27
Scitech Pharma Raises Over RMB 100 Million in Series A+ Financing to Accelerate Clinical Research of New Oncology Drugs
READ MORE -
2021-12-21
SciTech Pharma Signs Strategic Cooperation Agreement with Shanghai Oriental Hospital
READ MORE -
2021-10-08
SciTech Pharma Announces China NMPA Approval for ST-1703 for Treatment of Patients with HER2-Positive Advanced Solid Tumors
READ MORE -
2021-05-18
SciTech Pharma and LI Jin's team collaborate on ST-1898 clinical phase I trial
READ MORE
